Peptide directoryBrain, hypothalamus & pituitary

Phoenixin-20

The longer phoenixin, cut from the same precursor as the short one.

Where it comes from

Made in
The same tissues as phoenixin-14
Sent out by
With phoenixin-14
Acts on
  • Pituitary
  • Hypothalamus
  • Heart

What it does

  • Acts like phoenixin-14 at the same proposed receptor, and the two are usually tested as interchangeable 1
  • Calms inflammation in cultured blood vessel lining cells, and eased pulmonary hypertension in rats 2
  • Named for the phoenix, as it rose from a search of the genome rather than from tissue 1

In medicine

  • No medicine copies it or blocks it, and it is not measured in people
  • Nothing in the clinic separates it from phoenixin-14: both are proposed to act at GPR173, for which no ligand is in use 3

Beyond the body’s own use

  • Nothing containing it is in trials, approved or obtainable outside the laboratory
  • Its own evidence is cardiopulmonary rather than reproductive: in rats given monocrotaline it lowered pulmonary artery pressure along with the inflammation and oxidative stress behind it, which is the one finding reported for the long form and not the short 2
  • What is unknown is whether the two forms are ever released separately. One precursor yields both, the longer is the less studied, and no assay in use tells them apart 1

Sources

  1. Stein et al., The phoenixins, from discovery of the hormone to identification of the receptor, Peptides 2018
  2. Chai et al., Phoenixin-20 ameliorates pulmonary arterial hypertension by inhibiting inflammation and oxidative stress, Aging 2024
  3. Stein et al., Hypothalamic action of phoenixin to control reproductive hormone secretion, the role of GPR173, American Journal of Physiology 2016

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.